NCT06355258

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Westlake University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are: * Does troxerutin lower the number of thrombotic events in participants? * What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients. Participants will: * Take troxerutin or a placebo every day for 7 days. * Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests * Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia

Conditions

• COVID 19 Associated Coagulopathy

Interventions

Type	Name	Description
DRUG	Troxerutin	Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
DRUG	Placebo	Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
DRUG	placebo + low molecular weight heparin	2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
DRUG	troxerutin + low molecular weight heparin	2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

Timeline

• Start date: 2023-12-15
• Primary completion: 2024-12-01
• Completion: 2025-03-01
• First posted: 2024-04-09
• Last updated: 2024-11-12

Locations

1 site across 1 country: China